Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17149688 | 0.86 | NPC1 (0.52) | MAPTMEN1KMT2ATP53POLB | |
| SCHEMBL17149708 | 0.80 | CYP1A2 (0.61) | MAPTMEN1HTTKMT2AALDH1A1 | |
| SCHEMBL17149915 | 0.77 | FLT3 (0.58) | MAPTMEN1KMT2AALDH1A1RXFP1 | |
| SCHEMBL25037752 | 0.77 | CNR1 (0.50) | MAPTMEN1HTTBLMKMT2A | |
| SCHEMBL18766888 | 0.76 | ALDH1A1 (0.45) | MAPTMEN1HTTBLMKMT2A | |
| SCHEMBL17737359 | 0.73 | KMT2A (0.76) | MAPTMEN1HTTBLMKMT2A | |
| SCHEMBL17149668 | 0.72 | NPC1 (0.67) | MEN1HTTKMT2AALDH1A1TRPV1 | |
| SCHEMBL17149795 | 0.72 | MEN1 (0.50) | MAPTMEN1KMT2AALDH1A1TRPV1 | |
| SCHEMBL29176348 | 0.72 | NPC1 (0.71) | MEN1KMT2AIDO1TP53POLB | |
| SCHEMBL17149778 | 0.72 | CYP1A2 (0.61) | MAPTMEN1KMT2AALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2019-03-21 | — | — | US | disclosed |
| US-10167257-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015150097-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | MAPT 3242/4885MEN1 3590/4885HTT 2611/4885 |
| US-10167257-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | MAPT 3259/4885MEN1 3708/4885HTT 2682/4885 |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | MAPT 3259/4885MEN1 3708/4885HTT 2682/4885 |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | MAPT 2895/4885MEN1 3774/4885HTT 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.